CIK 0001404644
- Non-accelerated filer
- Smaller reporting company
Neurogene Inc.
Sign in to watch- Ticker
- NGNE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 980542593
- Phone
- +1 877-237-5020
- Business address
- 535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY, 10011
- Former names
- Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2015-08-10 | PFIZER INC 10% owner | Sale | −9,901 | $37.23 | $369K | 1,183,640 |
| 2015-08-10 | PFIZER INC 10% owner | Sale | −10,544 | $36.37 | $383K | 1,173,096 |
| 2015-08-10 | PFIZER INC 10% owner | Sale | −11,627 | $38.49 | $448K | 1,161,469 |
| 2015-08-10 | PFIZER INC 10% owner | Sale | −12,726 | $25.32 | $322K | 1,148,743 |
| 2015-08-10 | PFIZER INC 10% owner | Sale | −13,109 | $26.32 | $345K | 1,135,634 |
| 2015-08-10 | PFIZER INC 10% owner | Sale | −25,931 | $20.35 | $528K | 1,109,703 |
| 2015-08-10 | PFIZER INC 10% owner | Sale | −31,400 | $24.31 | $763K | 1,078,303 |
| 2015-08-10 | PFIZER INC 10% owner | Sale | −44,268 | $22.60 | $1.0M | 1,034,035 |
| 2015-08-10 | PFIZER INC 10% owner | Sale | −58,632 | $23.41 | $1.4M | 975,403 |
| 2015-08-10 | JOHNSON & JOHNSON 10% owner | Sale | −231,455 | $31.66 | $7.3M | 1,383,366 |
| 2015-03-12 | SIMPSON TODD E Director | Grant or award · Stock Option (Right to Buy) | +5,000 | 5,000 | ||
| 2015-03-12 | SHREWSBURY STEPHEN B CMO; Senior VP Clinical Dev. | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2015-03-12 | Pelzer Robert Director | Grant or award · Stock Option (Right to Buy) | +5,000 | 5,000 | ||
| 2015-03-12 | Nolan Sean P. Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2015-03-12 | Main David President and CEO | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2015-03-12 | MacKenzie Lloyd VP Technical Operations | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2015-03-12 | LEVITT DANIEL J Director | Grant or award · Stock Option (Right to Buy) | +5,000 | 5,000 | ||
| 2015-03-12 | Bridger Gary Director | Grant or award · Stock Option (Right to Buy) | +5,000 | 5,000 | ||
| 2015-03-12 | Alam Kamran CFO, Vice President Finance | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2015-01-11 | Mitchell David Chilton VP Global Regulatory & Quality | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 |
Page 22 of 27 · 537 trades